Business Wire

BACARDI-LIMITED

Share
Bacardi Limited Announces Regional Leadership Moves

Bacardi Limited, the largest privately held spirits company in the world, today announces the retirement of Francis Debeuckelaere, Regional President Western Europe, Australia and New Zealand (EUROC), after nearly 30 years with Bacardi. Francis will retire from his role at the end of the fiscal year on March 31, 2023, and then will move to a consulting capacity to support the transition and provide expertise on company initiatives.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230313005216/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Francis Debeuckelaere retires from Bacardi at the end of the fiscal year following a 30-year career with the company. (Photo: Business Wire)

Francis’ is a true story of rising the ranks at Bacardi. From his first role in 1994 as a local Marketing Director, to managing the commercial side of market clusters, to ultimately becoming a regional president. Francis’ passion has always been about winning and building high performance teams which helped lead the way for solid results in EUROC. Equally as an absolute advocate of the on-trade, Francis also helped develop a global On-Trade Council which delivered incredible success and engagement with key customers and markets across the world.

It has been an honor to be a part of Bacardi and to build my spirits career here. This company is truly special, and I am glad to leave strong teams and brands behind,” says Francis Debeuckelaere. “I am proud of the work we have accomplished together and look forward to seeing Bacardi thrive for generations to come.”

“I want to give a heartfelt thank you to Francis for his many years of service. He is a true industry professional and a friend to many of us. His expertise and deep knowledge of the business and markets have played such an invaluable role in building our business and brands,” says Mahesh Madhavan, Chief Executive Officer of Bacardi Limited.

Following Francis’ retirement, Ignacio “Nacho” del Valle will take on the role of Regional President, Western Europe. A 25+ year veteran of Bacardi, Nacho has been serving as Regional President of Latin America and Caribbean (LAC) for the last six years, transforming the regional business by delivering growth in key markets and leading the premiumization of several categories. As a sixth generation Bacardí family member, Nacho is a true advocate for preserving the unique company culture and driving high engagement results.

“I look forward to this next chapter in my Bacardi journey and to continue driving brand love for our iconic portfolio,” says Ignacio “Nacho” del Valle. “It’s a tremendous responsibility and privilege to build upon the Bacardi legacy of generations before us.”

Pete Carr, who moves into the previously announced role of Global Growth Officer on April 1, will add leadership of Latin America and Caribbean (LAC) to his responsibilities. In addition to the region, Pete will lead global digital commerce, on-trade and route-to-market efforts.

Vijay Subramaniam, Regional President of AMEA and Global Travel Retail (GTR) adds Australia and New Zealand, formerly under the EUROC region, to his responsibilities.

About Bacardi Limited

Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded more than 161 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 8,000, operates production facilities in 10 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit http://www.bacardilimited.com or follow us on LinkedIn or Instagram.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230313005216/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union13.12.2024 07:00:00 CET | Press release

Atopic dermatitis is a common, chronic, and flaring inflammatory skin disease characterized by persistent itch and recurrent skin lesions, and affects approximately up to 40 million people in the European Union (EU)1-4 Prurigo nodularis is a serious skin disease characterized by chronic itch, skin nodules covering large body areas, and poor sleep quality, which is estimated to affect up to 111 people per 100,000 in the EU5-10 Nemolizumab is a first-in-class monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31.2 IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation and skin barrier dysfunction in both atopic dermatitis and prurigo nodularis11-13 This positive opinion from the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) recommending the granting of marketing authorization of nemolizumab in the European Union (EU) for the treatment of both atopic dermatitis and prurigo n

FPT and DENSO Sign MOU to Accelerate Software-Defined Vehicle Innovation13.12.2024 06:58:00 CET | Press release

Global IT corporation FPT and global automotive components manufacturer DENSO signed a Memorandum of Understanding (MOU) to collaborate on advancing software-defined vehicles (SDV). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212915049/en/ The signing ceremony took place at DENSO Corporation Aichi Headquarters with the participation of Dr Truong Gia Binh, Chairman of FPT Corporation, Mr Shinnosuke Hayashi, President & CEO of DENSO Corporation, and senior leaders of both companies. (Photo: Business Wire) Under this MOU, the two companies will develop software for next-generation SDVs, with a particular emphasis on mass-production projects for Advanced Driver Assistance Systems (ADAS). Both companies aim to build a high-speed, high-quality global development framework, with plans for expansion by the end of 2027. The partnership is backed by FPT’s two decades of experience in automotive, a global team of 5,000 automotive

Kao Corporation: Regarding Shareholder Statement13.12.2024 05:48:00 CET | Press release

Oasis Management Company Ltd. (hereinafter referred to as “Oasis Management”), an investment management firm and a shareholder of our company, released a statement regarding Director candidates to be proposed at our 119th Ordinary General Meeting of Shareholders. Kao's Board of Directors and management team strive to increase shareholder value from a long-term perspective based on our business strategy. For the purpose of enhancing our corporate value, we are committed to engaging directly and constructively with all our stakeholders and welcome new perspectives to address challenges. Kao is constantly evolving its selection process to ensure an optimal composition of the Board of Directors. This year, the Committee for Examination of Nominees for Directors and Audit & Supervisory Board Members spent more than six months discussing the matter before reaching a final decision, and the decision was made before Oasis Management proposed any director candidates. The timing of the announcem

BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor13.12.2024 01:30:00 CET | Press release

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it has entered into a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (“CSPC”) for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. SYH2039 targets solid tumors that have a mutation called MTAP deletion, which is estimated to be present in approximately 15 percent of all cancer types with the most common including glioblastoma, pancreatic cancer and non-small cell lung cancer. “With one of the most dynamic solid tumor portfolios in the industry, we are continually assessing opportunities that align with our strategic focus and address significant unmet needs for patients. This MAT2A inhibitor is a valuable addition to our solid tumor pipeline, and we’re eager to explore its potential, particularly in combination with our internally de

Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas12.12.2024 23:30:00 CET | Press release

Six Late-Stage Programs with Peak Revenue Potential of $10B - $20B1 Poised to Deliver Sustainable GrowthExpected Phase 3 Data Readouts in 2025 for Oveporexton (TAK-861), Zasocitinib (TAK-279) and Rusfertide (TAK-121)Regulatory Filings for Oveporexton (Narcolepsy Type 1), Zasocitinib (Psoriasis) and Rusfertide (Polycythemia Vera) on Track for Fiscal Years 2025 - 2026Five Additional Filings Anticipated in Fiscal Years 2027 - 2029 Including First Indication Submissions for Mezagitamab (TAK-079), Fazirsiran (TAK-999) and Elritercept (TAK-226) Takeda (TSE:4502/NYSE:TAK) willhost an investor R&D Day today beginning at 8:30 a.m. JST in Tokyo. The meeting will focus on programs in the company’s late-stage pipeline, the transformative value they could deliver to patients, and the market opportunities they represent. “We are focused on advancing our innovative pipeline and accelerating late-stage programs to deliver sustainable revenue growth to 2030 and beyond, building upon the strong momentum

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye